Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Prometic Biosciences enters into new product development program By PBR Staff Writer
ProMetic Life Sciences' UK subsidiary has signed an agreement with one of its existing multinational clients, a global leader in the biotherapeutics industry.
Drug Research > Drug Discovery & Development > News
National Institute of Allergy and Infectious Diseases awards SRI International Contract to study new therapies for HIV and AIDS SRI International has been awarded a new $49 million, seven-year contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to conduct preclinical development of potential therapies for HIV infection and AIDS.
Drug Research > Drug Discovery & Development > News Neurotrope, Mount Sinai to develop Bryostatin-1 for NPC treatment By PBR Staff Writer
Neurotrope Bioscience has entered into a license agreement with Icahn School of Medicine at Mount Sinai to use its information and data package for the development of Bryostatin-1 to treat Niemann-Pick Type C Disease (NPC).
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Mezzion Pharma begins clinical development program to evaluate Udenafil in adolescents with single ventricle heart defects
Mezzion Pharma has initiated a clinical program to evaluate the use of udenafil to treat adolescents who have undergone the Fontan surgical palliation for single ventricle heart defects.
Drug Research > Drug Discovery & Development > News
ArmaGen, Shire to develop AGT-182 for treatment of hunter syndrome
ArmaGen, a privately held biotechnology company, has announced that it has entered into a worldwide licensing and collaboration agreement with Shire plc to develop AGT-182, an investigational enzyme replacement therapy (ERT) for potential treatment of both the central nervous system (CNS) and somatic (body-related) manifestations of Hunter syndrome.
Drug Research > Drug Discovery & Development > News
Bristol-Myers enters into immuno-oncology collaboration with Ono Pharmaceutical
By PBR Staff Writer
Bristol-Myers Squibb (BMS) and Ono Pharmaceutical have entered into a strategic agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens for cancer patients in Japan, South Korea and Taiwan.
Drug Research > Drug Discovery & Development > News
IDT Biologika - A Strategic Partner for Your Sterile Liquid Dosage Forms
| By IDT Biologika
In the highly specialized world of sterile liquid dosage forms, IDT Biologika is a contract manufacturing organization with the experience, the capability and the commitment to excellence to offer you a strategic advantage in your commercialization process. Our expertise drives our activities into higher-value pharmaceutical and biotechnology applications.
Drug Research > Drug Discovery & Development > White Papers
Cynapsus Therapeutics commences Phase II clinical trials in US
Cynapsus Therapeutics, a specialty pharmaceutical company focused on Parkinson's disease, has announced that following communication from the United States Food and Drug Administration, Phase II clinical studies for APL-130277 will commence immediately.
Drug Research > Drug Discovery & Development > News
MYOS enters into R&D agreement with Cloud Pharmaceuticals
MYOS, an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, has entered into a research and development agreement with Cloud Pharmaceuticals.
Drug Research > Drug Discovery & Development > News
Isis Pharmaceuticals initiates Phase 2 study of ISIS-APO(a) in patients with high Lp(a)
Isis Pharmaceuticals announced the initiation of a Phase 2 study evaluating ISIS-APO(a) in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.
Drug Research > Drug Discovery & Development > News
Lilly, Immunocore to jointly discover and develop new cancer therapies
By PBR Staff Writer
US-based Eli Lilly and Company has entered into a co-discovery and co-development collaboration with British biotechnology firm Immunocore to research and potentially develop new T cell-based cancer therapies.
Drug Research > Drug Discovery & Development > News
BioLineRx reports results from Phase 1/2 study for celiac treatment
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today unblinded results from its Phase 1/2 study for BL-7010, a novel polymer for the treatment of celiac disease.
Drug Research > Drug Discovery & Development > News
ChromaDex begins first human clinical study to confirm ChromaDex's NIAGEN Nicotinamide Riboside will increase NAD+
ChromaDex, an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the initiation of the first human clinical study for its patented ingredient NIAGEN, the first and only commercially available form of nicotinamide riboside (NR).
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250